VYNE Logo

VYNE Therapeutics Inc. (VYNE) 

NASDAQ
Market Cap
$41.89M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
764 of 774
Rank in Industry
426 of 432

Largest Insider Buys in Sector

VYNE Stock Price History Chart

VYNE Stock Performance

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various …

Insider Activity of VYNE Therapeutics Inc.

Over the last 12 months, insiders at VYNE Therapeutics Inc. have bought $0 and sold $0 worth of VYNE Therapeutics Inc. stock.

On average, over the past 5 years, insiders at VYNE Therapeutics Inc. have bought $5.18M and sold $5.32M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 13,000 shares for transaction amount of $50,778 was made by LEPORE PATRICK G (director) on 2023‑11‑15.

List of Insider Buy and Sell Transactions, VYNE Therapeutics Inc.

2023-11-15Purchasedirector
13,000
0.3748%
$3.91$50,778-46.95%
2021-11-30Purchasedirector
12,500
0.024%
$1.02$12,699-55.58%
2021-08-25Purchasedirector
12,500
0.0243%
$1.60$20,000-62.28%
2021-08-16Sale10 percent owner
250,000
0.4697%
$1.74$435,000-64.78%
2021-08-13Sale10 percent owner
250,000
0.4967%
$1.84$460,000-64.61%
2021-08-12Sale10 percent owner
338,897
0.7299%
$2.23$755,740-68.34%
2021-05-26Purchasedirector
12,500
0.0241%
$3.60$44,958-68.32%
2021-05-06Sale10 percent owner
1M
2.0052%
$3.67$3.67M-65.17%
2021-03-15Purchasedirector
12,500
0.0259%
$7.41$92,563-79.34%
2021-01-28Purchase10 percent owner
4.22M
2.2941%
$2.37$10M-69.62%
2020-12-03Purchasedirector
100,000
0.078%
$1.71$170,850-46.15%
2020-09-08PurchasePresident and CEO
150,000
0.084%
$1.38$207,135+10.54%
2020-09-08PurchaseChief Financial Officer
80,000
0.0474%
$1.46$116,960+10.54%
2020-06-09Purchase10 percent owner
5.41M
3.4508%
$1.85$10M-19.14%
2018-07-24Sale
1M
4.3407%
$7.65$7.65M-11.34%
2018-01-25Purchase10 percent owner
200,000
0.6735%
$17.00$3.4M-71.72%
2018-01-25Purchase10 percent owner
530,000
1.7848%
$17.00$9.01M-71.72%
2018-01-25Purchase10 percent owner
588,236
1.9809%
$17.00$10M-71.72%
2018-01-25Purchasedirector
588,236
1.9809%
$17.00$10M-71.72%

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLC10 percent owner
4935057
33.4548%
$2.8424<0.0001%
Remeditex Ventures LLC10 percent owner
1582854
10.7302%
$2.8410
Domzalski DavidPresident and CEO
1315966
8.921%
$2.8410+10.54%
Saik AndrewChief Financial Officer
340000
2.3049%
$2.8410+10.54%
venBio Global Strategic Fund II L.P.10 percent owner
265000
1.7964%
$2.8410

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Cormorant Asset Management Lp$4.28M9.61.39M0%+$00.2
Eventide Asset Management$3.13M9.61.39M0%+$00.05
Citadel Advisors LLC$3.63M8.131.18M0%+$0<0.01
Dsc Advisors L P$2.14M4.79696,4650%+$03.46
Parkman Healthcare Partners Llc$2.14M4.79696,4700%+$00.27
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.